Opinion|Videos|July 5, 2024
Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease
Expert panelists discuss the implementation of a treat-to-target approach for the long-term management of inflammatory bowel disease (IBD), drawing upon data from the STARDUST and REACT-2 trials to support their recommendations and insights into optimizing patient outcomes through this strategy.
Advertisement
Episodes in this series
Advertisement
Related to this article
TRANSCEND-T2D-2 topline data show retatrutide lowered A1C more and produced over twice the weight loss of semaglutide 2 mg in type 2 diabetes.
Tom Martens, MD, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss CONNECT trial data on CGM in non-insulin-treated type 2 diabetes.
Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.
Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.
Jasmohan Bajaj, MD, MS, joins Nancy Reau, MD, and Kimberly Brown, MD, on who to screen for HE in clinic and how to prepare patients and families.
Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.
Dupilumab cut new or worsening allergies by 34% vs placebo in a 12-trial atopic dermatitis meta-analysis, suggesting it may slow the atopic march.
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Q&A: Mucus Plugging, Multimorbidity, and GOLD 2027, With Gerard Criner, MD
2
Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories
3
Omalizumab Biosimilar CT-P39: Quality of Life Gains Precede CSU Control
4
Diabetes Dialogue: Retatrutide Tops Semaglutide on A1C, Weight in T2D
5